Nervous systemic drug TOP10 came out! Yangzijiang, people's blessings...

Pharmaceutical Network January 27th, January 21st, the official website of the State Drug Administration shows that the hydrochloric acid right metomide injection has Yichang People's Fu Pharmaceuticals, Hunan Colum Pharmaceuticals, Chengdu Bert Pharmaceuticals and other 5 enterprises to supplement the application was approved;
, Jiangsu Hengrui Pharmaceutical's hydrochloric acid right metomide injection was also approved for supplementary application.
the first three quarters of 2020, the growth rate of the terminal neurological drugs market in key provincial and municipal hospitals declined by 18.25 percent year-on-year, according to the company's internal network data.
top10 manufacturers, there are Yangzijiang Pharmaceutical Group, Yichang Renfu Pharmaceuticals, Qilu Pharmaceuticals, Jiangsu Enhua Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals 5 domestic enterprises.
eight of the top 10 products are injections.
brand TOP10, 1 billion varieties of only Yangzijiang Pharmaceutical Group's Zosin injection, while the collection of "flying" hydrochloric acid right metomide injection to become the second largest brand;
neurological drugs to lift the storm again! Guangdong into the sale of "big households", the four sub-categories of the market on January 21, the State Drug Administration official website shows that hydrochloric acid right metomide injection has Yichang People's Fu Pharmaceuticals, Hunan Colum Pharmaceuticals, Chengdu Bert Pharmaceuticals and other 5 enterprises to supplement the application was approved;
Prior to this, Jiangsu Hengrui Pharmaceutical's hydrochloric acid right metomiding injection was also approved for supplementary application, Yangzijiang Pharmaceutical Group's propofol medium/long chain fat milk injection was approved for listing in the imitation of 4 categories, the product has been included in the fourth batch of national collection ... Behind a series of "actions", the market for neurological drugs may be storming again.
In recent years, the sales of terminal neurological drugs in key provincial and municipal public hospitals (units: 100 million yuan) Source: Mienet key provincial and municipal public hospitals terminal competition pattern Mi intranet data show that in recent years, the growth rate of public hospital terminal neurological drugs market in key provinces and cities slowed down, although the first three quarters of 2020 decreased by 18.25% YoY, but sales are still more than 10 billion yuan.
from the quarterly sales trend, the first quarter year-on-year decline of more than 35%, the second quarter year-on-year decline of 14%, the third quarter year-on-year decline of less than 5%, the market gradually rebounded.
In recent years, the urban pattern of terminal neurological drugs in key provincial and municipal public hospitals (units: 100 million yuan) Source: Minet key provinces and cities of public hospitals terminal competition pattern from the urban pattern, Guangdong, Shanghai, Jiangsu, Beijing, Shandong 5 provinces and cities have sales scale of more than 1 billion yuan, while Guangdong stand alone, more than 1.5 billion yuan.
TOP10 manufacturers, there are Yangzijiang Pharmaceutical Group, Yichang Renfu Pharmaceuticals, Qilu Pharmaceuticals, Jiangsu Enhua Pharmaceuticals, Jiangsu Hengrui Pharmaceuticals 5 domestic enterprises, of which, Yangzijiang Pharmaceuticals Group grew the fastest, more than 15%.
from the sub-pattern, psycho-excitement drugs, painkillers, anesthetics, psycho-stabilizers are the four major sub-categories, the total market share of more than 80%.
in terms of dosage forms, injections and tablets are the two mainstream dosage forms, with a combined market share of nearly 90%, while the remaining market share is divided by capsules, inhalers and other dosage forms.
top 8 injections to grab TOP10! Yangzijiang leader, people's heavy varieties over-evaluation, Hengrui exclusive products bright-eyed key provincial and municipal public hospital terminal neuro-chemical products TOP10 source: Mi-Net key provincial and municipal public hospital terminal competition pattern products TOP10 market share accounted for nearly 35% of the total proportion of neurological drugs.
dosage forms, all but eight were injections, except for inhalation of hexafluorane and o nitrogen tablets.
2020Q1-Q3 key provincial and municipal public hospital terminal neurotic drug brand TOP10 Source: Mi net key provincial and municipal public hospital terminal competition pattern brand TOP10, in addition to Fessen Yuscabi's propofol / long chain fat emulsion injection, Aspen propofol emulsion, NAPP hydroxycodone release tablets, domestic pharmaceutical companies occupy 7 seats.
Among them, 1 billion varieties only Yangzijiang Pharmaceutical Group's Zosin injection, while the collection "with fly" hydrochloric acid right metomide injection became the second largest brand;
In recent years, the sales of Zosin injections in key provincial and municipal public hospitals (units: 100 million yuan) Source: Minnet key provincial and municipal public hospitals terminal competition pattern Zosin developed by Wyeth-Ayerst Laboratory, adaptive disorders for the need to use opioid analgesics to treat a variety of pain.
intranet data show that in recent years in key provinces and cities in the public hospital terminal Zosin injection sales hit a new high, in 2019 exceeded the 2 billion mark.
Zosin injection is only Yangzijiang Pharmaceutical Group and Nanjing Yuke Pharmaceuticals two production enterprises, of which Yangzijiang Pharmaceutical Group's market share is unique, and Nanjing Yuke Pharmaceuticals was approved at the end of 2019, sales scale is small.
at present, the product has not been evaluated by enterprises, Enhua Pharmaceuticals, Tianjin Pharmaceutical Research Institute with a new classification to submit a listing application in the review and approval (in the drug review center), after approval will be treated as a review.
hydrochloric acid right metomide injection by Oricon Pharma and Abbott co-development, approved in the United States in 1999, followed by the European Union, Japan and other countries and regions listed for sale, in 2009 Jiangsu Hengrui Pharmaceuticals in china's first listing.
years, sales of right-to-metomidin injections at public hospital terminals in key provinces and cities have grown steadily, with a slight decline in the first three quarters of 2020 compared with the same period last year, according to
-meter intranet data.
hydrochloric acid right metomide injection competition is fierce, the current production enterprises have Jiangsu Hengrui Pharmaceuticals, Yangzijiang Pharmaceutical Group, Yichang Renfu Pharmaceuticals, Hunan Colum Pharmaceuticals and other 11, of which, Yangzijiang Pharmaceutical Group, China Pharmaceutical Group Industry, Jiangsu Hengrui Pharmaceuticals, Hunan Colum Pharmaceuticals and other 8 enterprises have been evaluated.
In addition, Jiangsu Huatai Chenguang Pharmaceuticals, Chenxin Pharmaceuticals and other 3 enterprises in the consistent evaluation of supplementary applications in the review and approval (in the drug review center), Jiangsu Zhengda Qingjiang Pharmaceuticals, Shijiazhuang Four Drugs, Nanjing Zhengda Tianqing Pharmaceuticals and other 6 enterprises to copy 3 categories of products in the review and approval (in the drug review center), after approval as the same review. according to
data, in June 2018, Yangzijiang Pharmaceutical Group's hydrochloric acid right metomide injection was approved for listing in 3 types of imitation, and was evaluated as follows, followed by the exclusive winning bid of 4-7 and the alliance region, the market share increased from less than 1% in 2018 to nearly 90% in the first three quarters of 2020, with sales up nearly 200% year-on-year.
In recent years, the sales of Bhutto morphine injections in key provincial and municipal public hospitals (units: 100 million yuan) Source: Minnet key provincial and municipal public hospitals terminal competition pattern of Bhutto morphine injections are the exclusive products of Jiangsu Hengrui Pharmaceuticals.
sales of Bhutto morphine injections in public hospitals in key provinces and cities have grown rapidly in recent years, from less than 50 million yuan in 2015 to more than 400 million yuan in 2019, according to the company's internal network data.
At present, the production enterprises of bhutolphine injection of citric acid are only Jiangsu Hengrui Pharmaceuticals, and the national pharmaceutical group Guorui Pharmaceutical Co., D.C.'s citric acid bhutolphine injections are in the review and approval (in the drug review center) in order to imitate the 3 categories of products reported in the review and approval.
source: Minet database, company announcement